Pharmaceuticals & Therapeutics

South Korea's Dong Bang Co Ltd is moving beyond commodity animal drugs, targeting high-barrier markets. Is its focus on proprietary tech a viable global strategy?

Hong Kong's NatureU touts impressive anti-aging results on a public registry, but a closer look reveals a complex strategy blending early science with savvy marketing.

A small biotech is about to reveal data on a novel drug that could change autoimmune care. Will its bold scientific strategy pay off for patients and investors?

As Pacira BioSciences fends off an activist investor, a high-stakes proxy fight pits long-term R&D against demands for short-term returns.

A small biotech just unveiled data for an oral weight-loss pill that appears twice as effective as a key competitor in early tests, shaking up the market.

A breakthrough biomarker, DNlite™, analyzes landmark trial data, offering a new way to identify high-risk diabetes patients missed by current standards.

With Brian Ewart's appointment as General Counsel, the nonprofit signals a new era of disciplined growth, leveraging top legal talent to navigate complex federal contracts.

Exigent Research Network's hire of Nina Chavez is more than a personnel move; it's a strategic play to decentralize and democratize cancer research.

With its new SYNMUE™ probiotic, SynbioTech is targeting the biological clock of our immune system. A deep dive into the science, the strategy, and the execution.

VFF's balance sheet didn't need the cash, so why take it? A deep dive into a strategic capital raise that's less about liquidity and more about legitimacy.

A new drug promises the brain-rewiring benefits of psychedelics without the trip. Can Clearmind Medicine's CMND-100 transform addiction treatment?

KB Home's Canoe Creek Reserve in St. Cloud is more than new housing; it's a test case for affordability, sustainable growth, and personalization in Central Florida.

Landmark trial results for Bayer's KERENDIA unlock a vast new market in non-diabetic kidney disease, offering hope to millions and a strategic win for the firm.

A private startup just achieved a nuclear first in 40 years. This rapid milestone, driven by new policy, signals a new era for energy innovation.

Chinese vaccine maker Zhengye Biotechnology has 180 days to save its Nasdaq listing. But the sub-$1 stock price is just a symptom of deeper financial decay.

Interim Phase 3 data shows Otsuka's VOYXACT not only meets surrogate endpoints but preserves kidney function, a strategic masterstroke in the competitive nephrology market.

A new class of doctor is bridging the gap between lab and patient. Meet the physician-scientists tackling deadly diseases with revolutionary new approaches.

The DEA is joining forces with 7,000 community coalitions for a landmark summit. We analyze if this new blueprint can finally disrupt the fentanyl crisis.

As Chair Ilona Haaijer announces her 2026 departure, Corbion's seamless succession plan reveals a masterclass in governance and strategic continuity.

A new alliance between Made Scientific and Pluristyx promises to slash the time and cost of developing advanced iPSC therapies. But can it deliver on its promise?